A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 in Combination With Gemcitabine in the Treatment of Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2015
At a glance
- Drugs Gemcitabine (Primary) ; Olaparib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2012 Planned End Date changed from 1 Aug 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 18 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.